SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549


                                    FORM 8-K


                                 Current Report
                     Pursuant to Section 13 or 15(d) of the
                         Securities Exchange Act of 1934


       Date of Report (Date of earliest event reported): February 6, 2004


                                 CRYOLIFE, INC.
             (Exact name of registrant as specified in its charter)


                                     Florida
                 (State or other jurisdiction of incorporation)


                   1-13165                      59-2417093
           (Commission File Number) (IRS Employer Identification No.)


              1655 Roberts Boulevard N.W., Kennesaw, Georgia 30144
              ----------------------------------------------------
          (Address of principal executive offices, including zip code)


                                 (770) 419-3355
              (Registrant's telephone number, including area code)


                                       N/A
          (Former name or former address, if changed since last report)













ITEM 5. OTHER EVENTS AND REGULATION FD DISCLOSURE.

On February 6, 2004, CryoLife issued a press release announcing an update on its
510K premarket  notification for CryoValve SG decellularized human heart valves.
CryoLife hereby  incorporates  by reference  herein the information set forth in
its Press Release dated February 6, 2004, a copy of which is attached  hereto as
Exhibit  99.1.  Except as  otherwise  provided in the press  release,  the press
release  speaks only as of the date of such press release and such press release
shall not create any  implication  that the affairs of CryoLife  have  continued
unchanged since such date.

Except for the historical  information  contained in this report, the statements
made  by  CryoLife  are  forward-looking   statements  that  involve  risks  and
uncertainties. All such statements are subject to the safe harbor created by the
Private  Securities  Litigation Reform Act of 1995.  CryoLife's future financial
performance could differ  significantly  from the expectations of management and
from results expressed or implied in the Press Releases. For further information
on other risk factors, please refer to CryoLife's Form 10-K, as amended, for the
year  ended  December  31,  2002,  as filed  with the  Securities  and  Exchange
Commission,  and CryoLife's  subsequent filings with the Securities and Exchange
Commission.  CryoLife disclaims any obligation or duty to update or modify these
forward-looking statements.

ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.

     (a)  Financial Statements.

          Not applicable.

     (b)  Pro Forma Financial Information.

          Not applicable.

     (c)  Exhibits.

          Exhibit Number         Description
          --------------         -----------

          99.1                   Press Release dated February 6, 2004




                                       2



                                   SIGNATURES

Pursuant to the  requirements of the Securities  Exchange Act of 1934,  CryoLife
has duly  caused  this  report  to be signed  on its  behalf by the  undersigned
hereunto duly authorized.

                                     CRYOLIFE, INC.



Date:  February 9, 2004              By: /s/ D. A. Lee
                                         ---------------------------------------
                                     Name:    D. Ashley Lee
                                     Title:   Vice President, Chief Financial
                                              Officer and Treasurer

                                       3



                                  EXHIBIT INDEX



Exhibit Number             Description
--------------             -----------

99.1                       Press Release dated February 6, 2004


                                       4